Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...
Vertex Pharmaceuticals operates in a profitable subsector and is poised for further success, says Dr Michael Tubbs ...
Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...
Issuing a so-called positive opinion, EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended Kaftrio as a combination therapy for CF patients aged two years and older with a ...
The committee supports approving the CFTR modulator for patients 2 years and older with at least one non-class I CFTR gene mutation.
The pharmaceutical industry with blockbuster drug potential represents a high-growth opportunity for investors seeking transformative returns. These companies invest heavily in research and ...
A new inhalable gene therapy for cystic fibrosis (CF) has entered Phase I clinical trials, a major milestone on the journey towards seeing this treatment in the clinic. For this first phase, the ...
Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results